Table 1. Survival of mice treated with UV-4 for 7 or 10 days starting at varied times relative to challenge.
| Initiation of Treatment | Vehicle, 10 days | UV-4, 7 Days | UV-4, 10 Days | Oseltamivir, 5 days | |||
|---|---|---|---|---|---|---|---|
| % Survival | % Survival | P value | % Survival | P value | % Survival | P value | |
| -1h | 20% | - | - | - | - | - | - |
| -1h | - | 90% | >0.0001 | 100% | >0.0001 | 100% | >0.0001 |
| +24h | - | 85% | >0.0001 | 95% | >0.0001 | 67% | 0.0005 |
| +48h | - | 50% | 0.0231 | 55% | >0.0001 | 55% | 0.0022 |
| +72h | - | 40% | 0.0423 | 40% | 0.0078 | 70% | 0.001 |
| +96h | - | 45% | 0.0494 | 10% | 0.08 | 40% | 0.001 |
| +120h | - | 30% | 0.25 | 30% | 0.39 | 10% | 0.013 |
Groups of BALB/c mice (n = 20, combined data from 2 experiments each having 10 animals/group) received the first treatment dose of 100 mg/kg of UV-4 or 20 mg/kg of oseltamivir phosphate at-1, 24, 48, 72, 96, or 120 h or vehicle control at-1h relative to infection with ~1 LD90 of INFV A/Texas/36/91 (H1N1) via IN instillation. Treatment began at the time point indicated relative to challenge with UV-4 dosing continued TID every 8 hours for a total of 7 or 10 days, while oseltamivir phosphate treatment continued BID for 5 days. Percent survival is presented along with statistical comparison using log rank tests of each treated group compared to the vehicle only control group.